All holdings
BioMarin Pharmaceutical BMRN
Source: the SEC Form 13F filings of the managers we follow, latest for Q3 2026. How we use them
Prices here are quarter-end prices implied by the 13F filings. Today’s price on Yahoo Finance
Share price change by quarter -14.6% Q3 ’24
-6.5% Q4 ’24
+7.5% Q1 ’25
-22.2% Q2 ’25
-1.5% Q3 ’25
+9.7% Q4 ’25
-4.9% Q1 ’26
+1.3% Q2 ’26
Q3 ’24: -14.6%; Q4 ’24: -6.5%; Q1 ’25: +7.5%; Q2 ’25: -22.2%; Q3 ’25: -1.5%; Q4 ’25: +9.7%; Q1 ’26: -4.9%; Q2 ’26: +1.3% Change in the quarter-end price implied by managers’ 13F filings, adjusted for stock splits. Excludes dividends.
Managers holding it, by quarter 1 Q4 ’23
1 Q1 ’24
1 Q2 ’24
1 Q3 ’24
1 Q4 ’24
1 Q1 ’25
1 Q2 ’25
1 Q3 ’25
1 Q4 ’25
1 Q1 ’26
1 Q2 ’26
0 Q3 ’26
Q4 ’23: 1; Q1 ’24: 1; Q2 ’24: 1; Q3 ’24: 1; Q4 ’24: 1; Q1 ’25: 1; Q2 ’25: 1; Q3 ’25: 1; Q4 ’25: 1; Q1 ’26: 1; Q2 ’26: 1; Q3 ’26: 0 Counts the managers on this site whose 13F for that quarter includes BioMarin Pharmaceutical.
Who holds it Each manager’s latest 13F, sorted by how much of their portfolio it is. Changes are against their previous quarter.
Managers holding BioMarin Pharmaceutical Manager Portfolio▼ Value Change Held for Dodge & Cox 0.4%$849m $849m ▲ Added +1.9%27 qtrs
Download the holders: CSV · JSON · Markdown
Directors buying and selling Open-market trades by directors, officers and 10% holders over the last 12 months. How this works From their Form 4 filings with the SEC. Grants, option exercises and shares sold to pay tax are left out.
Sort by Date (high to low) Date (low to high) Who (Z–A) Who (A–Z) Shares (high to low) Shares (low to high) Value (high to low) Value (low to high) Insider purchases and sales of BioMarin Pharmaceutical Date▼ Who Bought or sold Shares Price Value Filing 2 Sep 2026 Davis George EricEVP, Chief Legal Officer ▼ Sold 17,557 $66.28 $1.2m Form 4
About the company Sector Health care · Pharmaceutical Preparations Incorporated in Delaware Financial year ends 31 December Shares outstanding 194m at 28 Jul 2026 SEC filings Annual reports and other filings on EDGAR Revenue and profit $548m 2013
$890m 2015
$1.3bn 2017
$1.7bn 2019
$1.8bn 2021
$2.4bn 2023
$3.2bn 2025
2013: $548m; 2014: $749m; 2015: $890m; 2016: $1.1bn; 2017: $1.3bn; 2018: $1.5bn; 2019: $1.7bn; 2020: $1.9bn; 2021: $1.8bn; 2022: $2.1bn; 2023: $2.4bn; 2024: $2.9bn; 2025: $3.2bn BioMarin Pharmaceutical revenue and net income by year Year Revenue Net income 2025 $3.2bn $349m 2024 $2.9bn $427m 2023 $2.4bn $168m 2022 $2.1bn $142m 2021 $1.8bn −$64.1m 2020 $1.9bn $854m 2019 $1.7bn −$23.8m 2018 $1.5bn −$77.2m 2017 $1.3bn −$117m 2016 $1.1bn −$630m 2015 $890m −$172m 2014 $749m −$134m 2013 $548m −$176m
From the company’s XBRL financial statements filed with the SEC, for each financial year. Gaps mean the company didn’t report that figure in a standard form.
In fund portfolios US-registered funds run by these managers that hold BioMarin Pharmaceutical, from their latest N-PORT filings.
Funds holding BioMarin Pharmaceutical Fund Weight▼ Value As at Dodge & Cox Global Stock FundDodge & Cox 0.3% $43.4m 30 Jun 2026